The objective of the conducted research was to design 2 mm orodispersible minitablets of pediatric doses of hydrocortisone (0.5 mg; 1.0 mg) with desirable pharmaceutical properties and eliminate the sensation of a bitter taste using preparation of solid dispersion by ball mill. Hydrocortisone was selected as the model substance, as it is widely utilized in the pediatric population. ODMTs were prepared by compression (preceded by granulation) in a traditional single-punch tablet machine and evaluated using pharmacopoeial tests, DSC, and FTIR analysis. The methods used to evaluate the effectiveness of the taste-masking effect included in vivo participation of healthy volunteers, in vitro drug dissolution and utilization of an analytical device—“electronic tongue”. The research employed a preclinical animal model to preliminary investigate the bioequivalence of the designed drug dosage form in comparison to reference products. The study confirmed the possibility of manufacturing good-quality hydrocortisone ODMTs with a taste-masking effect owing to the incorporation of a solid dispersion in the tablet mass.
The aim of the study was to propose pharmacy-compounded oral gels as a new and alternative dosage form that is attractive to children as having a better masking taste than syrups and reducing the risk of spilling. The application and physical properties of the gels prepared with cellulose derivatives (hydroxyethylcellulose and carmellose sodium) or carbomers were evaluated. The results of the study showed the most suitable consistency, viscosity, and organoleptic properties for gels prepared with carbomer and cellulose derivatives at concentrations of 0.75% and 2.0%, respectively. The microbial stability of the gels was guaranteed by the use of methylparaben and potassium sorbate. VAL (valsartan) and CC (candesartan cilexetil) tablets, often used off-label in children, were pulverized and suspended in the hydrogel bases, resulting in final drug concentrations of 4 mg/g and 1 mg/g, respectively. There was no significant change in viscosity and consistency parameters when the pulverized tablets were added, and only small changes in viscosity and consistency were observed during 35 days of storage, especially in the gels with sodium carmellose and candesartan. On the basis of the drug assay, an expiry date of 25 °C was recommended: 35 days for valsartan and 14 days for candesartan preparations.
Background/Objectives: Vaginal administration enables optimal drug concentrations at the site of administration, but its effectiveness is limited by factors such as the vagina’s self-cleansing mechanisms and fluctuations in physiological conditions. Due to the difficulties in treating and the frequent recurrences of vaginal candidiasis, new drug formulations are required to ensure more effective therapy and sustained release of antifungal agents. Mucoadhesive vaginal sponges are a promising drug formulation providing prolonged release of the active ingredient and its contact with the vaginal mucosa. The application of polymers and their modifications plays a key role in the development of drug forms with unique and desired technological parameters. Methods: Therefore, the focus of this research was the development of a three-stage sodium alginate cross-linking technique based on polyelectrolyte complexes with gelatin and ɛ-poly-L-lysine, and additional ionic cross-linking with zinc ions, to obtain mucoadhesive vaginal sponges with an antifungal agent—luliconazole. The prepared formulations were evaluated for their pharmaceutical, mechanical, and mucoadhesive properties. In addition, antifungal and anti-biofilm action against Candida strains and compatibility with the vaginal VK2 E6/E7 epithelial cell line of the prepared sponges were assessed. Results: It was noted that the triple cross-linking process increased the mechanical properties of the developed sponges, improved mucoadhesive properties to vaginal mucosa of drug-loaded formulations, and demonstrated a sustained LUL release profile. Moreover, prepared sponges possessed improved antifungal and anti-biofilm effects against C. albicans, C. krusei, and C. parapsilosis. The prepared triple cross-linked formulations were biocompatible with the human vaginal VK2 E6/E7 epithelial cell line, depending on the exposure time and applied concentration. Conclusions: Triple cross-linked alginate sponges containing luliconazole were successfully prepared based on polyelectrolyte complexes with gelatin and ɛ-poly-L-lysine and additional ionic cross-linking with zinc ions. The triple cross-linking process of alginate improved the mechanical, mucoadhesive, and antifungal properties of the developed formulations.